SHANGHAI – Beijing-based Canbridge Life Sciences Inc. is a biotech that seeks to bring Western innovation to Chinese patients who have few if any treatment options.
SHANGHAI – Jiangsu Hengrui Medicine Co. Ltd., a billion-dollar integrated pharma with R&D centers in New Jersey, Shanghai and Chengdu, has been pushing in the direction of innovation faster and farther than most other Chinese pharmas. And with the recent announcement they will invest ¥850 million (US$137 million) in a biologics manufacturing plant, it's clear the execs aren't afraid to invest heavily in the high-risk area of large molecules and immunotherapy.
SHANGHAI – The Shanghai-based contract research organization/contract manufacturing powerhouse, Wuxi Apptec, is on the move again, this time demonstrating its ability to creatively leverage capital markets to fund expansionary plans.
SHANGHAI – China's stock market collapse over the past week has been on everyone's minds. Eyes have been glued to cell phone apps with greater concentration than ever before, checking minute to minute how fast and how far share prices will fall.
SHANGHAI – The Shanghai-based contract research organization/contract manufacturing powerhouse, Wuxi Apptec, is on the move again, this time demonstrating its ability to creatively leverage capital markets to fund expansionary plans.
SHANGHAI – China’s stock market collapse over the past week has been on everyone’s minds. Eyes have been glued to cell phone apps with greater concentration than ever before, checking minute to minute how fast and how far share prices will fall.
SHANGHAI – Hangzhou-based Ascletis Inc. is aiming for a home turf advantage with its interferon-free regimen for chronic hepatitis C, having submitted investigational new drug applications to both the Mainland Chinese and Taiwanese Food and Drug Administrations.
SHANGHAI – Shanghai's Cellular Biomedicine Group Inc. (CBMG) has added a cancer vaccine to its pipeline, a Gvax vaccine it intends to combine with a PD-1 drug in a U.S. phase II study for non-small-cell lung cancer (NSCLC).
SHANGHAI – Shanghai's Cellular Biomedicine Group Inc. (CBMG) has added a cancer vaccine to its pipeline, a Gvax vaccine it intends to combine with a PD-1 drug in a U.S. phase II study for non-small-cell lung cancer (NSCLC).
SHANGHAI – Hangzhou-based Ascletis Inc. is aiming for a home turf advantage with its interferon-free regimen for chronic hepatitis C, having submitted investigational new drug applications to both the Mainland Chinese and Taiwanese Food and Drug Administrations.
